Cognition (CGTX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$3.9M

Net income growth (year over year)

+41.61%

Net margin

—

Return on equity

−83.76%

EPS (trailing twelve months)

−$0.17

Book value per share

$0.35

P/E (trailing twelve months)

—

Price to book

2.24

Debt to assets

15.10%

Payout ratio

—

Dividend yield

—

Company profile

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

• How do I buy stock in Cognition (CGTX)?

  CGTX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.